| Detected | Trial | Change |
|---|---|---|
| 2026-08-12 | NCT07703436 Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who… |
Trial sites expanded: 0 -> 5 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-08-03 | NCT07742384 Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib | Phase 1 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06564324 | A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally… | Non Small Cell Lung Cancer | Recruiting |
| NCT07154706 | Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC… | Non-small Cell Lung Cancer (NSCLC) | Recruiting |
| NCT05303519 | SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | Glioma | Recruiting |
| NCT07712757 | Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma | Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation | Not Yet Recruiting |
| Phase 2 | |||
| NCT04919811 | Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC | Non Small Cell Lung Cancer | Active, Not Recruiting |
| NCT04395677 | A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene | Non Small Cell Lung Cancer | Active, Not Recruiting |
| NCT07703436 | Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who… | Grade 2 IDH1-mutant Glioma | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | Advanced Solid Tumor | Active, Not Recruiting |
| Phase 1 | |||
| NCT07742384 | Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib | Healthy Adult Participants | Not Yet Recruiting |